Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years.
Browse the report:http://www.orbisresearch.com/reports/index/pharmacovigilance-market-analysis-by-clinical-trial-phases-preclinical-studies-phase-i-1-phase-ii-2-phase-iii-3-phase-iv-4-trial-by-type-of-service-providers-in-house-contract-outsourcing-and-segment-forecasts-to-2020
Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.
Contract outsourcing pharmacovigilance market is expected to grow at a lucrative rate of over 13.1% during the forecast period. Service flexibility and cost effectiveness associated with outsourcing are some key factors accounting for the segment’s lucrative growth.
Further key findings from the study suggest:
Pharmacovigilance services found the largest application in phase 4/IV clinical trial studies in 2013. Greater applicability and relevance are some factors accounting for the segment’s market position.
Contract outsourcing was the most revenue generating service provider segment in 2013.
Request a sample of the report:http://www.orbisresearch.com/contacts/request-sample/60666
Minimization of upfront investments and reduction in fixed overhead costs are some factors expected to drive segment growth.
North America was the largest regional market, accounting for over 40.0% of the revenue in 2013. Presence of stringent healthcare regulations implemented by the U.S. FDA and high market penetration rates of electronic medical records are some factors responsible for its large share.
Buy the report@http://www.orbisresearch.com/contact/purchase/60666
Asia Pacific is identified as the most lucrative market. Presence of a large pool of skilled labor and favorable business environments are some factors expected to drive regional market growth. Rapidly improving healthcare infrastructure in the emerging economies of India and China is also expected to provide new growth opportunities to the market participants.
Key players of this market include Quintiles Transnational Corporation, PAREXEL International, Clinquest Group BV, Pharmaceutical Product Development, Accenture Plc., Boehringer Ingelheim GmbH and Cognizant Technology Solutions.
Providing customized end to end PV solutions & services and entering into strategic agreements are some key strategies adopted by these market players.
Major points From table Of Contents:
Chapter One: Executive Summary
Chapter Two: Pharmacovigilance Industry Outlook
Chapter Three: Pharmacovigilance Clinical Trial Phase Outlook
Chapter Four: Pharmacovigilance Type of Service Provider Outlook
Chapter Five: Pharmacovigilance Regional Outlook
Chapter Six: Competitive Landscape
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019